BDBM50105085 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol::CHEMBL895::N-cyclobutylmethyl-4,5alpha-epoxy-3,6alpha,14-morphinantriol::NALBUPHINE::US10231963, Table B.1::US10512644, Compound Nalbuphine::US11534436, Compound Table B.1::US9233167, Nalbuphine::US9656961, Example 00118::USRE49340, Rank 9

SMILES O[C@H]1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5O[C@@H]1[C@]2(CCN3CC1CCC1)c45

InChI Key InChIKey=NETZHAKZCGBWSS-CEDHKZHLSA-N

Data  19 KI  16 IC50  10 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 50105085   

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  0.980nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  0.980nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  0.980nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataKi:  1.30nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataIC50:  87nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataIC50:  87nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataEC50:  34nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataIC50:  88nMAssay Description:The Ki (binding affinity) for μ opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Jour...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataEC50:  21nMAssay Description:The EC50 and Imax for μ opioid receptors was determined using a [35S]GTPγS binding assay. This assay measures the functional properties of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataIC50:  87nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank

TargetMu-type opioid receptor(Homo sapiens (Human))
Alkermes Pharma Ireland

US Patent
LigandPNGBDBM50105085(17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alp...)
Affinity DataEC50:  34nMAssay Description:The Ki (binding affinity) for opioid receptors was determined using a competitive displacement assay as previously described in Neumeyer (Journal of ...More data for this Ligand-Target Pair
In DepthDetails US PatentDrugBank